Covaxin Phase 3 Results Show 81% Interim Clinical Efficacy, Says Bharat Biotech
The global pandemic has almost deteriorated the human race in this new century. After Conducting too much research and studies, India made a wonderful contribution by its Covaxin vaccine production. Bharat Brotech is on its verge of trials. More than 60% of the vaccine is contributed by India.
India proved that ” incredibility is not just a culture here but also a habit.”
Bharat Biotech has announced Phase 3 clinical trial results of covaxin, saying the vaccine demonstrates interim clinical efficacy of 81%,announcing a big success for mankind The phase 3 clinical trials for Covaxin involved 25,800 volunteers, making it the “largest trials ever conducted in it the India” in collaboration with the Indian Council of Medical Research (ICMR)
India is among the topmost countries in the world in the field of scientific research, positioned as one of the top five nations. India ranks 3rd in medical science all over the world and now it has proved itself.
Dr. Krishna Ella, chairman, and managing director, Bharat Biotech said, covaxin has successfully accomplished its phase 3 trials without prior infection after the second dose,” . He added further ” with today’s results from our phase 3 clinical trials, we have now reported data on our Covid- 19 vaccine from Phase 1, 2 and 3 trials involving around 27,000participants.